On July 11, 2023, ADC Therapeutics announced the suspension of enrollments in a mid-stage study of its blood cancer drug, following the death of seven patients and respiratory complications in five others. ADC Therapeutics has put its mid-stage trial of Zynlonta, a drug for a type of blood cancer, on hold following unexpected patient complications and fatalities. Key Points: Additional Points: Conclusion: Hematology/Oncology Latest Posts Did You Know? As of 2021, the estimated five-year survival rate for patients with DLBCL was about 63%.